Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers

P. Miner Jr; J. Plachetka; E. Orlemans; J. G. Fort; M. Sostek

首页> 外文期刊>Alimentary Pharmacology & Therapeutics >Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers

【24h】

Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers

机译：临床试验：以固定剂量的PN 400（萘普生/埃索美拉唑镁）与萘普生500毫克和肠溶衣索美拉唑20毫克的固定剂量组合，评估三剂量速释埃索美拉唑对胃酸的抑制作用：随机，开放标签一期健康志愿者研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aliment Pharmacol Ther 2010; 32: 414–424

机译：Aliment Pharmacol Ther 2010； 32：414–424

著录项

来源
《Alimentary Pharmacology & Therapeutics》 |2010年第3期|p.414-424|共11页
作者
P. Miner Jr; J. Plachetka; E. Orlemans; J. G. Fort; M. Sostek;
展开▼
作者单位

Oklahoma Foundation for Digestive Research, Oklahoma City, OK, USA.;

POZEN Inc., Chapel Hill, NC, USA.;

POZEN Inc., Chapel Hill, NC, USA.;

POZEN Inc., Chapel Hill, NC, USA.;

AstraZeneca US, Wilmington, DE, USA.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers. [J] . Miner P Jr, Plachetka J, Orlemans E, Alimentary pharmacology & therapeutics. . 2010,第3期

机译：临床试验：在固定剂量的PN 400（萘普生/埃索美拉唑镁）与萘普生500 mg和肠溶衣索美拉唑20 mg的固定剂量组合中，评估三种剂量速释埃索美拉唑对胃酸的抑制作用：随机，开放标签，第一阶段在健康志愿者中进行研究。
2. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO? (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers [J] . YoonJung Choi, HyeKyung Han, Dongseong Shin, Drug Design, Development and Therapy . 2015,第4期

机译：HCP1004（萘普生和埃索美拉唑锶的固定剂量组合）和VIMOVO的药代动力学和耐受性比较（市售的萘普生和埃索美拉唑镁的固定剂量组合）在健康志愿者中
3. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: Two randomized trials [J] . HochbergM.C., FortJ.G., SvenssonO., Current medical research and opinion . 2011,第6期

机译：肠溶性萘普生和速释埃索美拉唑的固定剂量组合与塞来昔布治疗膝部骨关节炎的疗效相当：两项随机试验
4. Evaluation of the Bioequivalence of the 20 mg /10 ml Doses of Two Injectable Preparations of Eptifibatide: A Randomized, Open-Label, Two-Period Crossover Study in Healthy Adult Male Chinese Volunteers [C] . Yanhui Gao, Baoqiu Li, Jun Sun Chinese international peptide symposium . 2011

机译：评价20mg / 10ml的两种可注射制剂的20mg / 10ml剂量的两种可注射制剂：在健康成年男性志愿者中随机，开放标签，双周交叉研究
5. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers [O] . YoonJung Choi, HyeKyung Han, Dongseong Shin, 2015

机译：HCP1004（萘普生和埃索美拉唑锶固定剂量组合）和VIMOVO®（萘普生和埃索美拉唑镁固定剂量组合）在健康志愿者中的药代动力学和耐受性比较
6. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone [O] . J. L. Goldstein, M. C. Hochberg, J. G. Fort, 2010

机译：临床试验：NSAID相关内镜胃溃疡的发病率为PN 400（Naproxen Plus eSomeprazole MagneSium）与单独的肠涂层萘普生

摘要

著录项

相似文献

相关主题

期刊订阅